Copyright (c) 2025 Dow Jones & Company, Inc. The articles, information, and content displayed on this webpage may include materials prepared and provided by third ...

Eli Lilly LLY-0.47%decrease; red down pointing triangle said its next generation weight-loss drug retatrutide helped people lose up to 28.7% of their body weight after more than a year of treatment, ...

Shares of French biotech Abivax (ABVX) climbed in Paris on Wednesday, in a move Reuters attributed to market speculation about a potential takeover bid from weight-loss drugmaker Eli Lilly (LLY). The ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Eli Lilly’s ...

Milana Vayntrub, an actress known for playing Lily Adams in AT&T commercials, raised $500K for Los Angeles wildfire victims by offering exclusive “flirty” photos of herself “After the L.A. fires this ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug. By Gina Kolata Gina Kolata has ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also looks ripe to announce a stock split. Eli Lilly's shares look attractive ...

Eli Lilly has unveiled the location of the third of its four large-scale manufacturing facilities that it plans to build in the U.S. The drugmaker has selected Huntsville, Alabama, as the site of a $6 ...

Retatrutide shows highest weight loss to date in trial Lilly says trial departures due to perceived excessive weight loss Retatrutide shows elevated skin-related side effects Dec 11 (Reuters) - Eli ...

Eli Lilly is positioned for a secular growth trajectory, leveraging its duopoly in diabetes and obesity therapies while investing heavily in pipeline diversification. LLY faces intensifying ...

Dec 9 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama, to expand U.S.

In the world of oncology drug development, the standard playbook is simple: Race to earlier lines of treatment, where patient populations are larger. But Eli Lilly is flipping that script with its ...